Comparative Effectiveness of Dual Antihypertensive Regimens in Patients After Percutaneous Coronary Intervention
NCT07683585
Summary
This prospective randomized open-label study aims to compare the effectiveness of two dual antihypertensive therapy regimens in patients with arterial hypertension and coronary artery disease after elective percutaneous coronary intervention (PCI) with coronary artery stenting. Patients requiring dual antihypertensive therapy will be randomized to receive either an angiotensin receptor blocker (ARB) combined with a thiazide diuretic or an ARB combined with a dihydropyridine calcium channel blocker. The study will evaluate blood pressure control, angina symptoms, quality of life, need for treatment intensification, and healthcare utilization during follow-up. Clinical status will be assessed at discharge and during telemedicine follow-up visits at 2 weeks, 4 weeks, and 12 weeks after hospital discharge. The primary endpoint is the percentage reduction in systolic and diastolic blood pressure. Secondary endpoints include frequency of angina episodes, exercise limitations, patient satisfaction with treatment, and medical consultations during follow-up. The study is investigator-initiated and plans to enroll at least 207 participants.
Eligibility
Inclusion Criteria: * Age 50 to 70 years * Arterial hypertension * Coronary artery disease * Hospitalization for elective percutaneous coronary intervention * Coronary artery stenting during the current hospitalization * Requirement for dual antihypertensive therapy * Treatment with beta-blockers, lipid-lowering therapy, and antiplatelet therapy * Ability and willingness to provide written informed consent Exclusion Criteria: * Refusal or inability to provide informed consent * Acute coronary syndrome * Active malignancy * Pulmonary embolism * Chronic kidney disease stage 4-5 * Type 2 diabetes mellitus * Contraindications or intolerance to study medications, including bilateral renal artery stenosis, hyperkalemia, hyperuricemia, or gout * Women of reproductive age * Permanent or persistent atrial fibrillation * Planned staged coronary stenting * Heart failure with reduced ejection fraction * Any other condition that, in the investigator's opinion, may interfere with participation in the study or interpretation of study results
Conditions4
Interventions2
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
NCT07683585